Owens & Minor Misses Q4 Non-GAAP EPS Expectations in 2023 by $0.12

Trending News 🌧️

Owens & Minor ($NYSE:OMI) announced their Q4 financial results for 2023, missing Non-GAAP EPS expectations by $0.12. This came as a surprise to investors, who had been expecting the company to meet or exceed their previous earnings estimates. The news caused a sharp decline in Owens & Minor’s stock price, as investors reacted to the unexpected earnings report. Analysts noted that the company’s revenue was slightly lower than expected, but the primary cause of the lower-than-expected earnings was a one-time charge related to an asset impairment.

Owens & Minor has been struggling for some time, but this latest shortfall in Non-GAAP earnings has further compounded investor worries about the future of the company. While management is hopeful that they can recover in coming quarters, they acknowledged that they need to do more to meet earnings expectations going forward.

Price History

T h e n e w s a r o u n d O w e n s & M i n o r i s m o s t l y n e g a t i v e a s o f l a t e . 3 , r e s u l t i n g i n a 2 1 . 1 2 . T h i s n e w s a p p e a r s t o h a v e h a d a s i g n i f i c a n t i m p a c t o n s e n t i m e n t f o r t h e s t o c k a n d h a s c a u s e d i n v e s t o r s t o p u l l b a c k f r o m t h e s t o c k a t t h i s t i m e. Live Quote…

About the Company

Income Snapshot

Below shows the total revenue, net income and net margin for OMI. More…

Cash Flow Snapshot

Below shows the cash from operations, investing and financing for OMI. More…

Balance Sheet Snapshot

Below shows the total assets, liabilities and book value per share for OMI. More…

Key Ratios Snapshot

Some of the financial key ratios for OMI are shown below. More…

Analysis

As GoodWhale, we have performed an analysis of OWENS & MINOR’s wellbeing. From our Risk Rating, we determine that OWENS & MINOR is a medium risk investment from a financial and business standpoint. In our analysis, we have also noted two risk warnings that may be present in their income sheet and balance sheet. If you’d like to know more about these warnings, please become a registered user to access the information. More…

Peers

Owens & Minor Inc is in the business of distributing medical supplies and providing related services to healthcare providers. The company operates in North America and Europe. Its competitors include Orthofix Medical Inc, Medirect Latino Inc, PT Millennium Pharmacon International Tbk.

– Orthofix Medical Inc ($NASDAQ:OFIX)

Orthofix Medical Inc is a medical device company that provides orthopedic solutions to patients worldwide. The company has a market cap of 297.51M as of 2022 and a Return on Equity of -4.8%. The company’s products are used in the treatment of various conditions, including osteoarthritis, degenerative disc disease, scoliosis, and deformities. The company’s products are sold through a network of distributors and retailers.

– Medirect Latino Inc ($OTCPK:MLTO)

PT Millennium Pharmacon International Tbk is a leading pharmaceutical company in Indonesia with a market cap of 156.7B as of 2022. The company has a strong focus on research and development, and has a strong portfolio of products. The company has a Return on Equity of 17.77%.

Summary

Owens & Minor, Inc., a healthcare services provider, has recently reported that their fourth quarter non-GAAP earnings per share (EPS) in 2023 have fallen short by $0.12 from its expected target. Following the announcement, investor reception has been largely bearish, resulting in a decline in the stock’s price. Analyzing the company, it is clear that the current financial environment is having a negative impact on its performance, a trend that investors should pay attention to when considering investments.

Furthermore, price to earnings (P/E) ratios are also on the rise and caution investors against buying at current levels. While there may be some potential for growth in the long run, investors should retain a level of caution when deciding whether to invest in Owens & Minor.